DNMT3B
DNMT3B (DNA methyltransferase 3 beta) is a nuclear DNA (cytosine-5)-methyltransferase required for genome-wide de novo DNA methylation. It helps establish DNA methylation patterns during development and contributes to gene silencing. Browse Assay Genie's current range of DNMT3B research reagents below, or read on for the biology behind the target.
DNMT3B is a DNA methyltransferase that is required for genome-wide de novo methylation and is essential for establishing DNA methylation patterns during development. This methylation is coordinated with methylation of histones. DNMT3B may preferentially methylate nucleosomal DNA within the nucleosome core region. NCBI Gene describes the enzyme as functioning in de novo methylation rather than maintenance methylation, which sets it apart from the maintenance role usually associated with DNMT1.
DNMT3B also acts outside direct DNA methylation. It may function as a transcriptional co-repressor by associating with CBX4, independently of DNA methylation, and it acts as a co-repressor through association with ZHX1. It seems to be involved in gene silencing and is required for DUX4 silencing in somatic cells. In association with DNMT1, and through recruitment of CTCFL/BORIS, it is involved in activating BAG1 expression by modulating dimethylation of promoter histone H3 at H3K4 and H3K9.
The DNMT3B protein belongs to the class I-like SAM-binding methyltransferase superfamily and the C5-methyltransferase family. HGNC places the DNMT3B gene in the PWWP domain containing group and among the 7BS C5-cytosine DNA/RNA methyltransferases. The protein localises primarily to the nucleus and its expression is developmentally regulated. CpG methylation is important for embryonic development, imprinting and X-chromosome inactivation. Mutations in the gene cause immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described; isoforms 4 and 5 are probably not functional because two conserved methyltransferase motifs are deleted.
DNMT3B is required for genome-wide de novo methylation, making it a central enzyme for studying how CpG methylation patterns are established.
Its expression is developmentally regulated and it is essential for establishing methylation patterns during development, including imprinting and X-chromosome inactivation.
DNMT3B associates with CBX4 and ZHX1 as a transcriptional co-repressor and is required for DUX4 silencing in somatic cells.
Mutations in the DNMT3B gene cause immunodeficiency-centromeric instability-facial anomalies syndrome, linking the enzyme to a defined human genetic disorder.
DNMT3B is a DNA methyltransferase required for genome-wide de novo methylation and for establishing DNA methylation patterns during development. It may preferentially methylate nucleosomal DNA, and it can also act as a transcriptional co-repressor, for example with CBX4 or ZHX1.
HGNC names the gene DNA methyltransferase 3 beta; UniProt calls the protein DNA (cytosine-5)-methyltransferase 3B. An earlier name was DNA (cytosine-5-)-methyltransferase 3 beta. Eight alternatively spliced transcript variants are described, and isoforms 4 and 5 are probably not functional.
Mutations in the DNMT3B gene cause ICF syndrome. A mouse ortholog, Dnmt3b, exists, and mouse studies show that DNA methylation is required for mammalian development. Check the datasheet of any product for its validated reactivity.
Other DNA methyltransferases and epigenetic regulators with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9UBC3; product specifications from Assay Genie datasheets.